In December, SynapDx raised $6m in its series B round from venture capital firms North Bridge Venture Partners and General Catalyst Partners.

New York-listed Laboratory Corporation of America (LabCorp) has invested $2m in SynapDx to help it develop its blood-based autism spectrum disorder (ASD) diagnostic test.

In December, SynapDx raised $6m in its series B round from venture capital firms North Bridge Venture Partners and General Catalyst Partners.

In June 2010, SynapDx raised $9m in it’s A round from the two VCs and a third, Bain Capital Ventures.

David King, executive chairman of LabCorp, said: “SynapDx has the potential to revolutionize ASD diagnosis and offer pediatricians, patients and families the opportunity to begin treatment earlier, a key factor in improving ASD outcomes.”